Clinical trials: Burn Joints
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Restrictive Burn Scars
Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars
This Phase II, double-blind, randomized, placebo-controlled pilot study is designed to determine whether injection of autologous fibroblasts can increase the mobility (decrease the restriction) of burn scars.
- Trial name
- NCT01858753
- Testing
- Autologous fibroblasts
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Castle Creek Biosciences, LLC.
Burn
Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl
The objective of this study is to evaluate the difference in joint range of motion of a new flexible hydrogel nanoparticle wound dressing compared to typical sodium carboxymethylcellulose dressing Aquacel AG for treatment of…
- Trial name
- ROM (NCT01062191)
- Testing
- Aquacel AG, typical carboxymethylcellulose dressing, Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- ULURU Inc.
Restrictive Burn Scars of Joint Area
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to stable restrictive burn scars of an affected joint area.
- Trial name
- NCT00620737
- Testing
- Autologous Human Fibroblasts (Isolagen TherapyTM)
- Where
- 3 sites in United States
- Sponsor
- Castle Creek Biosciences, LLC.